Quick Answer
IONIS PHARMACEUTICALS INC reported Operating Income Loss of -$381.68 million for the year ending 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +19.7% in Operating Income Loss from 2024 to 2025.
- This data is from IONIS PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), IONIS PHARMACEUTICALS INC's Operating Income Loss has declined by 2,822.5%.
- Historical annual values: Fiscal year 2025: -$381.68 million | Fiscal year 2024: -$475.08 million | Fiscal year 2023: -$353.73 million | Fiscal year 2022: -$410.19 million | Fiscal year 2021: -$30.19 million | Fiscal year 2020: -$172.08 million | Fiscal year 2019: $365.88 million | Fiscal year 2018: -$61.37 million | Fiscal year 2017: $31.05 million | Fiscal year 2016: -$20.16 million | Fiscal year 2015: -$75.76 million | Fiscal year 2014: -$47.73 million | Fiscal year 2013: -$51.67 million | Fiscal year 2012: -$68.92 million | Fiscal year 2011: -$71.10 million | Fiscal year 2010: -$48.36 million | Fiscal year 2009: -$27.54 million | Fiscal year 2008: -$13.06 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: